Downregulation of CD46 during muscle differentiation: Implications for gene transfer to human skeletal muscle using group B adenoviruses

Human Gene Therapy

Volumn 19, Issue 2, 2008, Pages 133-142

  Larochelle, Nancy ^a   Deol, Jatinderpal R ^a,b   Srivastava, Vinit ^a,b   Allen, Carol ^a   Mizuguchi, Hiroyuki ^c   Karpati, George ^a,b   Holland, Paul C ^a,b   Nalbantoglu, Josephine ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DYSTROPHIN; MEMBRANE COFACTOR PROTEIN;

ADENOVIRUS; ARTICLE; CELL ADHESION; CELL CULTURE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; GENE TRANSFER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MUSCLE BIOPSY; MUSCLE DEVELOPMENT; MYOBLAST; PROTEIN EXPRESSION; SKELETAL MUSCLE;

ADENOVIRIDAE; ANTIGENS, CD46; BETA-GALACTOSIDASE; BIOPSY; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; MUSCLE FIBERS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; COXSACKIEVIRUS;

EID: 39449119197     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.040     Document Type: Article

References (41)

1. ACSADI, G., JANI, A., HUARD, J., BLASCHUK, K., MASSIE, B., HOLLAND, P., LOCHMULLER, H., and KARPATI, G. (1994a). Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants. Gene Ther. 1, 338-340.
2. ACSADI, G., JANI, A., MASSIE, B., SIMONEAU, M., HOLLAND, P., BLASCHUK, K., and KARPATI, G. (1994b). A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum. Mol. Genet. 3, 579-584.
3. AMALFITANO, A., and PARKS, R.J. (2002). Separating fact from fiction: Assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr. Gene Ther. 2, 111-133.
4. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURTJONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
5. DIPAOLO, N., NI, S., GAGGAR, A., STRAUSS, R., TUVE, S., LI, Z.Y., STONE, D., SHAYAKHMETOV, D., KIVIAT, N., TOURE, P., SOW, S., HORVAT, B., and LIEBER, A. (2006). Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol. Ther. 13, 756-765.
6. DUBOIS, C., FIGARELLA-BRANGER, D., PASTORET, C., RAMPINI, C., KARPATI, G., and ROUGON, G. (1994). Expression of NCAM and its polysialylated isoforms during mdx mouse muscle regeneration and in vitro myogenesis. Neuromuscul. Disord. 4, 171-182.
7. GAGGAR, A., SHAYAKHMETOV, D.M., and LIEBER, A. (2003). CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9, 1408-1412.
8. GAGGAR, A., SHAYAKHMETOV, D.M., LISZEWSKI, M.K., ATKINSON, J.P., and LIEBER, A. (2005). Localization of regions in CD46 that interact with adenovirus. J. Virol. 79, 7503-7513.
9. GAO, W., ROBBINS, P.D., and GAMBOTTO, A. (2003). Human adenovirus type 35: Nucleotide sequence and vector development. Gene Ther. 10, 1941-1949.
10. GONÇALVES, M.A., HOLKERS, M., CUDRÉ-MAUROUX, C., VAN NIEROP, G.P., KNAÄN-SHANZER, S., VAN DER VELDE, I., VALERIO, D., DE VRIES, A.A. (2006). Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: Robust dystrophin synthesis in Duchenne muscular dystrophy muscle cells. Mol. Ther. 13, 976-986.
11. GUIBINGA, G.H., EBIHARA, S., NALBANTOGLU, J., HOLLAND, P., KARPATI, G., and PETROF, B.J. (2001). Forced myofiber regeneration promotes dystrophin gene transfer and improved muscle function despite advanced disease in old dystrophic mice. Mol. Ther. 4, 499-507.
12. HAVENGA, M.J., LEMCKERT, A.A., OPHORST, O.J., VAN MEIJER, M., GERMERAAD, W.T., GRIMBERGEN, J., VAN DEN DOEL, M.A., VOGELS, R., VAN DEUTEKOM, J., JANSON, A.A., DE BRUIJN, J.D., UYTDEHAAG, F., QUAX, P.H., LOGTENBERG, T., MEHTALI, M., and BOUT, A. (2002). Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 76, 4612-4620.
13. JOHNSTONE, R.W., LOVELAND, B.E., and MCKENZIE, I.F. (1993). Identification and quantification of complement regulator CD46 on normal human tissues. Immunology 79, 341-347.
14. LOCHMULLER, H., JOHNS, T., and SHOUBRIDGE, E.A. (1999). Expression of the E6 and E7 genes of human papillomavirus (HPV16) extends the life span of human myoblasts. Exp. Cell Res. 248, 186-193.
15. MACCALMAN, C.D., BARDEESY, N., HOLLAND, P.C., and BLASCHUK, O.W. (1992). Noncoordinate developmental regulation of N-cadherin, N-CAM, integrin, and fibronectin mRNA levels during myoblast terminal differentiation. Dev. Dyn. 195, 127-132.
16. MAENPAA, A., JUNNIKKALA, S., HAKULINEN, J., TIMONEN, T., and MERI, S. (1996). Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am. J. Pathol. 148, 1139-1152.
17. MARTTILA, M., PERSSON, D., GUSTAFSSON, D., LISZEWSKI, M.K., ATKINSON, J.P., WADELL, G., and ARNBERG, N. (2005). CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J. Virol. 79, 14429-14436.
18. MIZUGUCHI, H., and HAYAKAWA, T. (2002). Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 285, 69-77.
19. NALBANTOGLU, J., PARI, G., KARPATI, G., and HOLLAND, P.C. (1999). Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum. Gene Ther. 10, 1009-1019.
20. NALBANTOGLU, J., LAROCHELLE, N., WOLF, E., KARPATI, G., LOCHMULLER, H., and HOLLAND, P.C. (2001). Muscle-specific overexpression of the adenovirus primary receptor CAR overcomes low efficiency of gene transfer to mature skeletal muscle. J. Virol. 75, 4276-4282.
21. NI, S., BERNT, K., GAGGAR, A., LI, Z.Y., KIEM, H.P., and LIEBER, A. (2005). Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum. Gene Ther. 16, 664-677.
22. OPHORST, O.J., KOSTENSE, S., GOUDSMIT, J., DE SWART, R.L., VERHAAGH, S., ZAKHARTCHOUK, A., VAN MEIJER, M., SPRANGERS, M., VAN AMERONGEN, G., YUKSEL, S., OSTERHAUS, A.D., and HAVENGA, M.J. (2004). An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 22, 3035-3044.
23. PIMORADY-ESFAHANI, A., GROUNDS, M.D., and MCMENAMIN, P.G. (1997). Macrophages and dendritic cells in normal and regenerating murine skeletal muscle. Muscle Nerve 20, 158-166.
24. POULIOT, Y., GRAVEL, M., and HOLLAND, P.C. (1994). Developmental regulation of M-cadherin in the terminal differentiation of skeletal myoblasts. Dev. Dyn. 200, 305-312.
25. REA, D., HAVENGA, M.J., VAN DEN ASSEM, M., SUTMULLER, R.P., LEMCKERT, A., HOEBEN, R.C., BOUT, A., MELIEF, C.J., and OFFRINGA, R. (2001). Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 166, 5236-5244.
26. ROELVINK, P.W., LIZONOVA, A., LEE, J.G., LI, Y., BERGELSON, J.M., FINBERG, R.W., BROUGH, D.E., KOVESDI, I., and WICKHAM, T.J. (1998). The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72, 7909-7915.
27. RUOSLAHTI, E. (2000). Targeting tumor vasculature with homing peptides from phage display. Semin. Cancer Biol. 10, 435-442.
28. SAKURAI, F., MIZUGUCHI, H., YAMAGUCHI, T., and HAYAKAWA, T. (2003). Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol. Ther. 8, 813-821.
29. SAKURAI, F., KAWABATA, K., KOIZUMI, N., INOUE, N., OKABE, M., YAMAGUCHI, T., HAYAKAWA, T., and MIZUGUCHI, H. (2006). Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice. Gene Ther. 13, 1118-1126.
30. SEGERMAN, A., ATKINSON, J.P., MARTTILA, M., DENNERQUIST, V., WADELL, G., and ARNBERG, N. (2003). Adenovirus type 11 uses CD46 as a cellular receptor. J. Virol. 77, 9183-9191.
31. SESHIDHAR, R.P., GANESH, S., LIMBACH, M.P., BRANN, T., PINKSTAFF, A., KALOSS, M., KALEKO, M., and CONNELLY, S. (2003). Development of adenovirus serotype 35 as a gene transfer vector. Virology 311, 384-393.
32. SHAYAKHMETOV, D.M., LI, Z.Y., NI, S., and LIEBER, A. (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 78, 5368-5381.
33. SHOUBRIDGE, E.A., JOHNS, T., and BOULET, L. (1996). Use of myoblast cultures to study mitochondrial myopathies. Methods Enzymol. 264, 465-475.
34. SINNREICH, M., SHAW, C.A., PARI, G., NALBANTOGLU, J., HOLLAND, P.C., and KARPATI, G. (2005). Localization of coxsackie virus and adenovirus receptor (CAR) in normal and regenerating human muscle. Neuromuscul. Disord. 15, 541-548.
35. ST GEORGE, J.A. (2003). Gene therapy progress and prospects: Adenoviral vectors. Gene Ther. 10, 1135-1141.
36. TOMKO, R.P., XU, R., and PHILIPSON, L. (1997). HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U.S.A. 94, 3352-3356.
37. TSUJIMURA, A., SHIDA, K., KITAMURA, M., NOMURA, M., TAKEDA, J., TANAKA, H., MATSUMOTO, M., MATSUMIYA, K., OKUYAMA, A., NISHIMUNE, Y., OKABE, M., and SEYA, T. (1998). Molecular cloning of a murine homologue of membrane cofactor protein (CD46): Preferential expression in testicular germ cells. Biochem. J. 330, 163-168.
38. TUVE, S., WANG, H., WARE, C., LIU, Y., GAGGAR, A., BERNT, K., SHAYAKHMETOV, D., LI, Z., STRAUSS, R., STONE, D., and LIEBER, A. (2006). A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J. Virol. 80, 12109-12120.
39. VERHAAGH, S., DE JONG, E., GOUDSMIT, J., LECOLLINET, S., GILLISSEN, G., DE VRIES, M., VAN LEUVEN, K., QUE, I., OUWEHAND, K., MINTARDJO, R., WEVERLING, G.J., RADOSEVIC, K., RICHARDSON, J., ELOIT, M., LOWIK, C., QUAX, P., and HAVENGA, M. (2006). Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J. Gen. Virol. 87, 255-265.
40. VOGELS, R., ZUIJDGEEST, D., VAN RIJNSOEVER, R., HARTKOORN, E., DAMEN, I., DE BETHUNE, M.P., KOSTENSE, S., PENDERS, G., HELMUS, N., KOUDSTAAL, W., CECCHINI, M., WETTERWALD, A., SPRANGERS, M., LEMCKERT, A., OPHORST, O., KOEL, B., VAN MEERENDONK, M., QUAX, P., PANITTI, L., GRIMBERGEN, J., BOUT, A., GOUDSMIT, J., and HAVENGA, M. (2003). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77, 8263-8271.
41. 5 promote adenovirus internalization but not virus attachment. Cell 73, 309-319.